Appointment of Joint Broker

19^th Sep 2016

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the appointment of N+1 Singer as Joint Broker to the Company, alongside Panmure Gordon, with immediate effect. Panmure Gordon remains Nominated Adviser to the Company.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
Panmure Gordon (UK) Limited Peter Steel Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Quo-Test supports improved medical management of diabetic retinopathy patients

SensLab is sponsoring the 36th Leipzig Triathlon

SensLab, an EKF Diagnostics company, will be testing triathletes lactate levels at the 36^th Leipzig Triathlon to be held at Kulkwitzer on the 28^th July 2019.

Bugs Runny: New study identifies bugs that help runners

A recent article in Nature Medicine by Scheiman et al has identified a strain of gut microbes present in marathon runners that improves run times. The scientists at Harvard and the Joslin Institute took poop samples from 15 runners at the 2015 Boston marathon.

EKF at AACC - Anaheim, California 2019

EKF's DiaSpect Tm hemoglobin analyzer supports anemia study in resource limited West Africa

Battery powered point-of-care analyzer demonstrated as ideal for operation in extreme temperatures and remote areas.